Log In Sign up
The largest database of trusted experimental protocols

Pneumotrac 6800

Manufactured by Vitalograph
Visit Supplier
Sourced in United Kingdom

The Pneumotrac 6800 is a portable spirometry device designed for measuring and recording lung function parameters. It is capable of performing various respiratory tests, including forced expiratory volume (FEV) and forced vital capacity (FVC) measurements.

Automatically generated - may contain errors

Lab products found in correlation

Uk bileve axiom array, by Thermo Fisher Scientific (2 mentions)

13 protocols using pneumotrac 6800

1

Lung Function Assessment in COPD

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
All participants except those with contraindications12 had lung function assessed using a personal computer-based spirometer (Pneumotrac 6800, Vitalograph, Buckingham, UK) by trained technicians. After conducting some practice exhalations, the results of at least two reproducible measurements (difference of at least two forced expiratory volume in 1 s and forced vital capacity <150 mL) were recorded. The spirograms of those with symptom-based or doctor-diagnosed COPD were reviewed independently for quality by two authors (OK and KBHL) following the European Respiratory Society/American Thoracic Society (ERS/ATS) guidelines.13 (link) Out of 1586 doctor-diagnosed/symptom-based COPD participants, 55 (3.5%) did not have lung function tests conducted due to contraindications, 1282 (83.7%) of those with lung function tests had acceptable spirometry and 600 (37.8%) had COPD confirmed by spirometry (defined by lower limit of normal criteria) based on prebronchodilator measured lung function.14 (link)
Kurmi O.P., Davis K.J., Hubert Lam K.B., Guo Y., Vaucher J., Bennett D., Wang J., Bian Z., Du H., Li L., Clarke R, & Chen Z. (2018). Patterns and management of chronic obstructive pulmonary disease in urban and rural China: a community-based survey of 25 000 adults across 10 regions. BMJ Open Respiratory Research, 5(1), e000267.
+ Open protocol
+ Expand
2

UK BiLEVE Genome-Wide Discovery Study

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
A genome-wide discovery study for variants associated with lung function measures was performed in 48,943 individuals from the UK BiLEVE16 (link) subset of UK Biobank (UK BiLEVE, stage 1). In brief, UK Biobank comprised 502,682 individuals of whom 275,939 were of self-reported European-ancestry and had ≥2 Forced Expired Volume in 1s (FEV1) and Forced Vital Capacity (FVC) measures (Vitalograph Pneumotrac 6800, Buckingham, UK) passing ATS/ERS criteria46 (link). Based on the best (highest) available FEV1 measurement, 50,008 individuals from groups with extreme low (n=10,002), near-average (n=10,000) and extreme high (n=5,002) % predicted FEV1 were selected from amongst never-smokers (total n=105,272) and the same numbers from amongst the heavy-smokers (mean 35 pack-years of smoking, total n=46,758). FEV1, FVC and FEV1/FVC distributions are summarised in Supplementary Figure 8. Genotyping was undertaken using the Affymetrix Axiom UK BiLEVE array16 (link) and imputed to the 1000 Genomes Project Phase 147 (link) and UK10K48 ,49 (link) combined panel. A total of 27,624,732 imputed or directly genotyped autosomal variants with imputation quality (info) >0.5 and minor allele count (MAC) ≥3 were included in the analysis. In total, 48,943 unrelated individuals passed all quality control steps and were used in this analysis.
Wain L.V., Shrine N., Soler Artigas M., Erzurumluoglu A.M., Noyvert B., Bossini-Castillo L., Obeidat M., Henry A.P., Portelli M.A., Hall R.J., Billington C.K., Rimington T.L., Fenech A.G., John C., Blake T., Jackson V.E., Allen R.J., Prins B.P., Campbell A., Porteous D.J., Jarvelin M.R., Wielscher M., James A.L., Hui J., Wareham N.J., Zhao J.H., Wilson J.F., Joshi P.K., Stubbe B., Rawal R., Schulz H., Imboden M., Probst-Hensch N.M., Karrasch S., Gieger C., Deary I.J., Harris S.E., Marten J., Rudan I., Enroth S., Gyllensten U., Kerr S.M., Polasek O., Kähönen M., Surakka I., Vitart V., Hayward C., Lehtimäki T., Raitakari O.T., Evans D.M., Henderson A.J., Pennell C.E., Wang C.A., Sly P.D., Wan E.S., Busch R., Hobbs B.D., Litonjua A.A., Sparrow D.W., Gulsvik A., Bakke P.S., Crapo J.D., Beaty T.H., Hansel N.N., Mathias R.A., Ruczinski I., Barnes K.C., Bossé Y., Joubert P., van den Berge M., Brandsma C.A., Paré P.D., Sin D.D., Nickle D.C., Hao K., Gottesman O., Dewey F.E., Bruse S.E., Carey D.J., Kirchner H.L., Jonsson S., Thorleifsson G., Jonsdottir I., Gislason T., Stefansson K., Schurmann C., Nadkarni G., Bottinger E.P., Loos R.J., Walters R.G., Chen Z., Millwood I.Y., Vaucher J., Kurmi O.P., Li L., Hansell A.L., Brightling C., Zeggini E., Cho M.H., Silverman E.K., Sayers I., Trynka G., Morris A.P., Strachan D.P., Hall I.P, & Tobin M.D. (2017). Genome-wide association analyses for lung function and chronic obstructive pulmonary disease identify new loci and potential druggable targets. Nature genetics, 49(3), 416-425.
+ Open protocol
+ Expand
3

Assessing Health Metrics Using UKB

Check if the same lab product or an alternative is used in the 5 most similar protocols
UKB allowed estimation of self-reported health status, chronic pain, and frailty and measured lung function. Participants reported their health as excellent, good, fair, or poor. Reported pain anywhere in the body (back; facial; headaches; hip; knee; neck/shoulder; stomach/abdominal) was considered as chronic pain if it lasted for more than 3 months. Grip strength was measured in both hands using a hydraulic hand dynamometer and the maximum reading was categorized into sex-specific quintiles. The prevalence of frailty was estimated using a modified Fried Frailty phenotype (13 (link)) and included two or more of self-reported weight loss, self-reported exhaustion, self-reported slow walking pace, or low measured grip strength (lowest quintile, sex specific). The low physical activity criteria were excluded from our definition as this is also a component of the CRS. A previous study showed that a four-criteria definition of Fried Frailty, excluding physical activity, had good specificity (0.98) but lower sensitivity (0.62) (14 (link)). Lung function was assessed by Vitalograph Pneumotrac 6800 spirometer and forced expiratory volume in 1 second (categorized into sex-specific quintiles).
Atkins J.L., Delgado J., Pilling L.C., Bowman K., Masoli J.A., Kuchel G.A., Ferrucci L, & Melzer D. (2018). Impact of Low Cardiovascular Risk Profiles on Geriatric Outcomes: Evidence From 421,000 Participants in Two Cohorts. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 74(3), 350-357.
+ Open protocol
+ Expand
4

Baseline Spirometry Measurements and Airflow Obstruction

Check if the same lab product or an alternative is used in the 5 most similar protocols
During the baseline examination all participants were requested to do a prebronchodilator spirometry (Pneumotrac 6800; Vitalograph, Buckingham, UK) to measure FEV 1 and FVC. If reproducibility between the first two blow was acceptable (≤5 % difference in FEV 1 & FVC), no additional blow was required. The highest recorded value of FEV 1 and FVC was utilized for the analysis. In 226 cases only one acceptable spirometry was available. Individuals were excluded if absolute values were <0.4 L or >8 L for FEV 1 or <0.6 L or >9 L for FVC. Airflow obstruction was present if FEV 1 /FVC<0.7. Percent of predicted values (from here on denoted %pred) of FEV 1 and FVC was calculated according to the Global Lung Function Initiative formula [16] .
Rydell A., Janson C., Lisspers K., Lin Y.T, & Ärnlöv J. (2024). FEV1 and FVC as robust risk factors for cardiovascular disease and mortality: Insights from a large population study. Respiratory medicine, 227.
+ Open protocol
+ Expand
5

Comprehensive Physiological Biomarkers Assessment

Check if the same lab product or an alternative is used in the 5 most similar protocols
In physiological biomarkers, we included FEV1, FVC, FEV1/FVC ratio, heel bone mineral density, hemoglobin concentration, and blood pressure. These biomarkers have been used for disease diagnoses and were previously found associated with morbidity and mortality. FEV1 and FVC were measured by breath spirometry using a Vitalograph Pneumotrac 6800. Heel bone mineral density was estimated based on the Quantitative Ultrasound Index through the calcaneus. From the index, an estimate is made of bone mineral density in grams/cm2.
Kuo C., Pilling L.C., Kuchel G.A., Ferrucci L, & Melzer D. (2019). Telomere length and aging‐related outcomes in humans: A Mendelian randomization study in 261,000 older participants. Aging Cell, 18(6), e13017.
+ Open protocol
+ Expand
6

Comprehensive Upper Limb Assessment Protocol

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
In a clinical trial compatible mode, each subject was assessed as follows: 1) performance of upper limb (PUL) module, a validated 74 point functional scale for motor performance relating to everyday life activity;[19 (link), 20 (link)]; 2) muscle strength for shoulder flexion, elbow extension and flexion, and wrist extension measured in lbs using a hand-held myometer (Microfet, Hoggan, UT); 3) MyoSet (Myopinch, Myogrip and Moviplate), a suite of recently validated novel tools to assess strength and fatigability of the upper limb;[21 (link), 22 (link)]; 4) Egen Klassification (EK2) interview version 2, which is used to determine performance of tasks in daily life (total score = 51)[23 (link)]; 5) spirometry and peak cough flow using a Vitalograph Pneumotrac 6800; and 6) record of time to loss of ambulation (LOA) in months.
Ricotti V., Evans M.R., Sinclair C.D., Butler J.W., Ridout D.A., Hogrel J.Y., Emira A., Morrow J.M., Reilly M.M., Hanna M.G., Janiczek R.L., Matthews P.M., Yousry T.A., Muntoni F, & Thornton J.S. (2016). Upper Limb Evaluation in Duchenne Muscular Dystrophy: Fat-Water Quantification by MRI, Muscle Force and Function Define Endpoints for Clinical Trials. PLoS ONE, 11(9), e0162542.
+ Open protocol
+ Expand
7

UK BiLEVE Genome-Wide Discovery Study

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
A genome-wide discovery study for variants associated with lung function measures was performed in 48,943 individuals from the UK BiLEVE16 (link) subset of UK Biobank (UK BiLEVE, stage 1). In brief, UK Biobank comprised 502,682 individuals of whom 275,939 were of self-reported European-ancestry and had ≥2 Forced Expired Volume in 1s (FEV1) and Forced Vital Capacity (FVC) measures (Vitalograph Pneumotrac 6800, Buckingham, UK) passing ATS/ERS criteria46 (link). Based on the best (highest) available FEV1 measurement, 50,008 individuals from groups with extreme low (n=10,002), near-average (n=10,000) and extreme high (n=5,002) % predicted FEV1 were selected from amongst never-smokers (total n=105,272) and the same numbers from amongst the heavy-smokers (mean 35 pack-years of smoking, total n=46,758). FEV1, FVC and FEV1/FVC distributions are summarised in Supplementary Figure 8. Genotyping was undertaken using the Affymetrix Axiom UK BiLEVE array16 (link) and imputed to the 1000 Genomes Project Phase 147 (link) and UK10K48 ,49 (link) combined panel. A total of 27,624,732 imputed or directly genotyped autosomal variants with imputation quality (info) >0.5 and minor allele count (MAC) ≥3 were included in the analysis. In total, 48,943 unrelated individuals passed all quality control steps and were used in this analysis.
Wain L.V., Shrine N., Soler Artigas M., Erzurumluoglu A.M., Noyvert B., Bossini-Castillo L., Obeidat M., Henry A.P., Portelli M.A., Hall R.J., Billington C.K., Rimington T.L., Fenech A.G., John C., Blake T., Jackson V.E., Allen R.J., Prins B.P., Campbell A., Porteous D.J., Jarvelin M.R., Wielscher M., James A.L., Hui J., Wareham N.J., Zhao J.H., Wilson J.F., Joshi P.K., Stubbe B., Rawal R., Schulz H., Imboden M., Probst-Hensch N.M., Karrasch S., Gieger C., Deary I.J., Harris S.E., Marten J., Rudan I., Enroth S., Gyllensten U., Kerr S.M., Polasek O., Kähönen M., Surakka I., Vitart V., Hayward C., Lehtimäki T., Raitakari O.T., Evans D.M., Henderson A.J., Pennell C.E., Wang C.A., Sly P.D., Wan E.S., Busch R., Hobbs B.D., Litonjua A.A., Sparrow D.W., Gulsvik A., Bakke P.S., Crapo J.D., Beaty T.H., Hansel N.N., Mathias R.A., Ruczinski I., Barnes K.C., Bossé Y., Joubert P., van den Berge M., Brandsma C.A., Paré P.D., Sin D.D., Nickle D.C., Hao K., Gottesman O., Dewey F.E., Bruse S.E., Carey D.J., Kirchner H.L., Jonsson S., Thorleifsson G., Jonsdottir I., Gislason T., Stefansson K., Schurmann C., Nadkarni G., Bottinger E.P., Loos R.J., Walters R.G., Chen Z., Millwood I.Y., Vaucher J., Kurmi O.P., Li L., Hansell A.L., Brightling C., Zeggini E., Cho M.H., Silverman E.K., Sayers I., Trynka G., Morris A.P., Strachan D.P., Hall I.P, & Tobin M.D. (2017). Genome-wide association analyses for lung function and chronic obstructive pulmonary disease identify new loci and potential druggable targets. Nature genetics, 49(3), 416-425.
+ Open protocol
+ Expand
8

Biomarker Measurement and Lung Function Evaluation

Check if the same lab product or an alternative is used in the 5 most similar protocols
The detailed information of the measurements was provided on the UK Biobank. The UK Biobank has collected biological samples of all 500,000 participants and measured a series of biochemical markers at baseline. The concentration of 25(OH)D was measured in a range from 10 to 375 nmol/L. Serum vitamin D level was determined by a direct competitive Chemiluminescent Immunoassay. A series of robust and comprehensive quality procedures was established to reduce drift, bias, and measurement uncertainty. A rigorous external quality assurance (EQA) and internal quality control (QC) protocol guided the evaluation of biomarkers. The lung function test is not undertaken if participants were pregnant (1st or 3rd trimester), being treated for tuberculosis, had history of a collapsed lung, a detached retina, had a chest infection in the last month or a heart attack, eye surgery, chest, or abdominal surgery in the previous 3 months. Lung function measurements were recorded using a spirometer (Vitalograph Pneumotrac 6800) with two or three blows and were guaranteed to be acceptable and reproducible. The good reproducibility of the first two blows was defined as a < 5% difference in FVC and FEV1, and the third blow was deemed unnecessary. Investigators determined whether the spirometry was adequate and acceptable.
Zhu Y., Jing D., Liang H., Li D., Chang Q., Shen M., Pan P., Liu H, & Zhang Y. (2022). Vitamin D status and asthma, lung function, and hospitalization among British adults. Frontiers in Nutrition, 9, 954768.
+ Open protocol
+ Expand
9

Baseline Spirometry Measurements Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Forced expiratory volume (FEV1) and forced vital capacity (FVC) were measured at baseline using Vitalograph Pneumotrac 6800 (Vitalograph, UK). Spirometry was not conducted if participants had experienced a chest infection in the last month; had a life-time history of detached retina or collapsed lung; if they had been through a heart attack, eye surgery or surgery to chest or abdomen in last 3 months; or if they were currently pregnant or on tuberculosis medications. If the reproducibility of the first two measurements was adequate, defined as a ≤ 5% difference in FVC and FEV1, a third measurement was not required. Post-bronchodilator spirometry was not available, although drug treatment was not withheld. The spirometry measurements were internally standardized by age, sex and height before analysis.
Magnus M.C., Henderson J., Tilling K., Howe L.D, & Fraser A. (2018). Independent and combined associations of maternal and own smoking with adult lung function and COPD. International Journal of Epidemiology, 47(6), 1855-1864.
+ Open protocol
+ Expand
10

Pulmonary Function Assessment for COPD

Check if the same lab product or an alternative is used in the 5 most similar protocols
Pulmonary function will be assessed by hand-held spirometry called Vitalograph Pneumotrac 6800 (Vitalograph, Buckingham, UK) to confirm and assess the severity of COPD. The test will be performed if there was no previous test done within a 3 month period. The spirometry test will be done following standard guidelines.37 The device will be calibrated on daily basis and participants will be assessed for contraindications prior to performing the test.
Alqahtani K.A., Gerlis C., Nolan C.M., Gardiner N., Szczepura A., Man W., Singh S.J, & Houchen-Wolloff L. (2022). SPACE FOR COPD delivered as a maintenance programme on pulmonary rehabilitation discharge: protocol of a randomised controlled trial evaluating the long-term effects on exercise tolerance and mental well-being. BMJ Open, 12(4), e055513.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!